A review on the association between glucagon-like peptide-1 receptor agonists and thyroid cancer

Experimental Diabetes Research

Volumn 2012, Issue , 2012, Pages

  Chiu, Wei Yih ^a,b   Shih, Shyang Rong ^a,b   Tseng, Chin Hsiao ^a,b  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITONIN; CYCLIC AMP; EXENDIN 4; GLUCAGON; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; LIRAGLUTIDE; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; PLACEBO; ROSIGLITAZONE; TETRAHYDROLIPSTATIN; DRUG DERIVATIVE; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE RECEPTOR; GLUCAGON RECEPTOR; GLUCAGON-LIKE PEPTIDE RECEPTOR; PEPTIDE; VENOM;

CALCITONIN BLOOD LEVEL; CANCER GROWTH; CELL HYPERPLASIA; CELL PROLIFERATION; CLINICAL TRIAL (TOPIC); DIABETES MELLITUS; EXPERIMENTAL STUDY; FOOD AND DRUG ADMINISTRATION; GENE EXPRESSION; HUMAN; IMMUNOREACTIVITY; IN VITRO STUDY; NEOPLASM; NONHUMAN; OBESITY; OBSERVATIONAL STUDY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIMATE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW; RNA TRANSCRIPTION; SENSITIVITY AND SPECIFICITY; THYROID CANCER; THYROID FOLLICLE CELL; THYROID MEDULLARY CARCINOMA; TUMOR VOLUME; ANIMAL; DISEASE MODEL; DRUG POTENTIATION; GENE EXPRESSION REGULATION; MACACA FASCICULARIS; METABOLISM; MOUSE; RAT; THYROID TUMOR;

ANIMALS; CLINICAL TRIALS AS TOPIC; DIABETES COMPLICATIONS; DIABETES MELLITUS; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; GLUCAGON-LIKE PEPTIDE 1; HUMANS; MACACA FASCICULARIS; MICE; PEPTIDES; RATS; RECEPTORS, GLUCAGON; THYROID NEOPLASMS; VENOMS;

EID: 84862291156     PISSN: 16875214     EISSN: 16875303     Source Type: Journal    
DOI: 10.1155/2012/924168     Document Type: Review

References (36)

1. Mojsov S., Weir G. C., Habener J. F., Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas Journal of Clinical Investigation 1987 79 2 616 619 (Pubitemid 17009701)
2. Nauck M. A., Heimesaat M. M., Orskov C., Holst J. J., Ebert R., Creutzfeldt W., Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type- 2 diabetes mellitus Journal of Clinical Investigation 1993 91 1 301 307 (Pubitemid 23037285)
3. Buse J. B., Rosenstock J., Sesti G., Schmidt W. E., Montanya E., Brett J. H., Zychma M., Blonde L., Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6) The Lancet 2009 374 9683 39 47
4. Chia C. W., Egan J. M., Incretin-based therapies in type 2 diabetes mellitus Journal of Clinical Endocrinology and Metabolism 2008 93 10 3703 3716
5. Simonsen L., Holst J. J., Deacon C. F., Exendin-4, but not glucagon-like peptide-1, is cleared exclusively by glomerular filtration in anaesthetised pigs Diabetologia 2006 49 4 706 712 (Pubitemid 43357544)
6. Kolterman O. G., Kim D. D., Shen L., Ruggles J. A., Nielsen L. L., Fineman M. S., Baron A. D., Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus American Journal of Health-System Pharmacy 2005 62 2 173 181 (Pubitemid 40674548)
7. Madsen K., Knudsen L. B., Agersoe H., Nielsen P. F., Thgersen H., Wilken M., Johansen N. L., Structure-activity and protraction relationship of long-acting glucagon-like peptide-1 derivatives: importance of fatty acid length, polarity, and bulkiness Journal of Medicinal Chemistry 2007 50 24 6126 6132
8. Knudsen L. B., Nielsen P. F., Huusfeldt P. O., Johansen N. L., Madsen K., Pedersen F. Z., Thgersen H., Wilken M., Agers H., Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration Journal of Medicinal Chemistry 2000 43 9 1664 1669 (Pubitemid 30304999)
9. Agers H., Jensen L. B., Elbrnd B., Rolan P., Zdravkovic M., The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men Diabetologia 2002 45 2 195 202 (Pubitemid 34208381)
10. Gier B., Butler P. C., Lai C. K., Kirakossian D., DeNicola M. M., Yeh M. W., Glucagon like peptide-1 receptor expression in the human thyroid gland Journal of Clinical Endocrinology and Metabolism 2012 97 1 121 131
11. Knudsen L. B., Madsen L. W., Andersen S., Almholt K., De Boer A. S., Drucker D. J., Gotfredsen C., Egerod F. L., Hegelund A. C., Jacobsen H., Jacobsen S. D., Moses A. C., Mlck A. M., Nielsen H. S., Nowak J., Solberg H., Thi T. D. L., Zdravkovic M., Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation Endocrinology 2010 151 4 1473 1486
12. Victoza (liraglutide injection): Human relevance of rodent thyroid C-cell tumors. 2009, http://www.fda.gov/downloads/AdvisoryCommittees/ Committees20MeetingMaterials/Drugs/ EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM151129.pdf
13. Parks M., Rosebraugh C., Weighing risks and benefits of liraglutidethe FDA's review of a new antidiabetic therapy New England Journal of Medicine 2010 362 9 774 777
14. Tseng C. H., Tseng C. P., Chong C. K., Huang T. P., Song Y. M., Chou C. W., Lai S. M., Tai T. Y., Cheng J. C., Increasing incidence of diagnosed type 2 diabetes in Taiwan: analysis of data from a national cohort Diabetologia 2006 49 8 1755 1760
15. Tseng C. H., Mortality and causes of death in a national sample of diabetic patients in Taiwan Diabetes Care 2004 27 7 1605 1609
16. Tseng C.-H., Diabetes and non-Hodgkin's lymphoma: analyses of prevalence and annual incidence in 2005 using the national health insurance database in Taiwan Annals of Oncology 2012 23 1 153 158
17. Tseng C.-H., Pioglitazone and bladder cancer: a population-based study of Taiwanese Diabetes Care 2012 35 2 278 280
18. Tseng C. H., Diabetes and risk of bladder cancer: a study using the National Health Insurance database in Taiwan Diabetologia 2011 54 8 2009 2015
19. Tseng C. H., Diabetes conveys a higher risk of gastric cancer mortality despite an age-standardised decreasing trend in the general population in Taiwan Gut 2011 60 6 774 779
20. Tseng C. H., Diabetes and risk of prostate cancer: a study using the National Health Insurance Diabetes Care 2011 34 3 616 621
21. Tseng C. H., Prostate cancer mortality in Taiwanese men: increasing age-standardized trend in general population and increased risk in diabetic men Annals of Medicine 2011 43 2 142 150
22. Tseng C. H., Chong C. K., Tseng C. P., Chan T. T., Age-related risk of mortality from bladder cancer in diabetic patients: a 12-year follow-up of a national cohort in Taiwan Annals of Medicine 2009 41 5 371 379
23. Tseng C. H., Chong C. K., Tai T. Y., Secular trend for mortality from breast cancer and the association between diabetes and breast cancer in Taiwan between 1995 and 2006 Diabetologia 2009 52 2 240 246
24. Vigneri P., Frasca F., Sciacca L., Pandini G., Vigneri R., Diabetes and cancer Endocrine-Related Cancer 2009 16 4 1103 1123
25. Giovannucci E., Harlan D. M., Archer M. C., Bergenstal R. M., Gapstur S. M., Habel L. A., Pollak M., Regensteiner J. G., Yee D., Diabetes and cancer: a consensus report Diabetes Care 2010 33 7 1674 1685
26. Dormandy J. A., Charbonnel B., Eckland D. J., Erdmann E., Massi-Benedetti M., Moules I. K., Skene A. M., Tan M. H., Lefbvre P. J., Murray G. D., Standl E., Wilcox R. G., Wilhelmsen L., Betteridge J., Birkeland K., Golay A., Heine R. J., Kornyi L., Laakso M., Mok M., Norkus A., Pirags V., Podar T., Scheen A., Scherbaum W., Schernthaner G., Schmitz O., krha J., Smith U., Tato J., Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial in macroVascular Events): a randomised controlled trial The Lancet 2005 366 9493 1279 1289 (Pubitemid 41416583)
27. Dormandy J., Bhattacharya M., Van Troostenburg De Bruyn A. R., Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: an overview of data from PROactive Drug Safety 2009 32 3 187 202
28. Elisei R., Bottici V., Luchetti F., Di Coscio G., Romei C., Grasso L., Miccoli P., Iacconi P., Basolo F., Pinchera A., Pacini F., Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10,864 patients with nodular thyroid disorders Journal of Clinical Endocrinology and Metabolism 2004 89 1 163 168 (Pubitemid 38183876)
29. Machens A., Hoffmann F., Sekulla C., Dralle H., Importance of gender-specific calcitonin thresholds in screening for occult sporadic medullary thyroid cancer Endocrine-Related Cancer 2009 16 4 1291 1298
30. Costante G., Meringolo D., Durante C., Bianchi D., Nocera M., Tumino S., Crocetti U., Attard M., Maranghi M., Torlontano M., Filetti S., Predictive value of serum calcitonin levels for preoperative diagnosis of medullary thyroid carcinoma in a cohort of 5817 consecutive patients with thyroid nodules Journal of Clinical Endocrinology and Metabolism 2007 92 2 450 455
31. Lamari Y., Boissard C., Moukhtar M. S., Jullienne A., Rosselin G., Garel J. M., Expression of glucagon-like peptide 1 receptor in a murine C cell line: regulation of calcitonin gene by glucagon-like peptide 1 FEBS Letters 1996 393 2-3 248 252 (Pubitemid 26298105)
32. Crespel A., De Boisvilliers F., Gros L., Kervran A., Effects of glucagon and glucagon-like peptide-1-(7-36) amide on C cells from rat thyroid and medullary thyroid carcinoma CA-77 cell line Endocrinology 1996 137 9 3674 3680 (Pubitemid 26284632)
33. Madsen L. W., Knauf J. A., Gotfredsen C., Pilling A., Sjgren I., Andersen S., Andersen L., De Boer A. S., Manova K., Barlas A., Vundavalli S., Berg Nyborg N., Knudsen L. B., Moelck A. M., Fagin J. A., GLP-1 receptor agonists and the thyroid: C-cell effects in mice are mediated via the GLP-1 receptor and not associated with RET activation Endocrinology 2012 153 3 1538 1547
34. Hegeds L., Moses A. C., Zdravkovic M., Le Thi T., Daniels G. H., GLP-1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP-1 analog, liraglutide Journal of Clinical Endocrinology and Metabolism 2011 96 3 853 860
35. Hay I. D., Papillary thyroid carcinoma Endocrinology and Metabolism Clinics of North America 1990 19 3 545 576 (Pubitemid 20282656)
36. Elashoff M., Matveyenko A. V., Gier B., Elashoff R., Butler P. C., Pancreatitis, pancreatic, and thyroid cancer with Glucagon-like peptide-1based therapies Gastroenterology 2011 141 1 150 156